<DOC>
	<DOCNO>NCT02664155</DOCNO>
	<brief_summary>In renally impaired patient acute venous thromboembolism ( VTE ) , standard-of-care ( SOC ) anticoagulation , i.e . heparins-vitamin K antagonist ( VKA ) , therapeutic dosage associate increase risk thromboembolic bleed complication compare patient normal renal function . Direct oral anticoagulant ( DOAs ) show least effective safe SOC VTE treatment . But clinical trial , moderate renally impaired patient poorly represent patient severe renal insufficiency . So dose reduction consider . Surprisingly , DOAs approve VTE treatment moderate severe renally impaired patient . There need evaluate reduce dose DOAs VTE treatment patient moderate severe renal insufficiency . We plan evaluate reduced dos 2 DOAs ( apixaban , rivaroxaban ) compare SOC VTE patient moderate severe renal insufficiency term net clinical benefit ( recurrent VTE major bleed ) 3 month .</brief_summary>
	<brief_title>Venous Thromboembolism Renally Impaired Patients Direct Oral Anticoagulants</brief_title>
	<detailed_description>In renally impaired patient acute venous thromboembolism ( VTE ) , standard-of-care ( SOC ) anticoagulation , i.e . heparins-vitamin K antagonist ( VKA ) , therapeutic dosage associate increase risk thromboembolic bleed complication compare patient normal renal function . These patient represent 20 % VTE population clinical practice . Direct oral anticoagulant ( DOAs ) show least effective safe SOC VTE treatment . But clinical trial , moderate renally impaired patient poorly represent ( &lt; 10 % ) patient severe renal insufficiency . So dose reduction consider . The new DOAs also develop stroke prevention atrial fibrillation ( SPAF ) . Patients include AF trial generally older prone present renal impairment ( &gt; 20 % ) VTE trial . So reduced dose DOAs evaluate show least effective , safe VKA subgroup patient moderate renal insufficiency ( creatinine clearance 30 50 ml/min ) . Surprisingly , DOAs approve VTE treatment SPAF moderate severe renally impaired patient ( creatinine clearance 15 30 mL/min ) . Moreover , patient receive reduce dose DOAs SPAF full dose DOAs VTE could associate increase bleeding risk , suggest subgroup analysis . So , , need evaluate reduce dose DOAs VTE treatment patient moderate severe renal insufficiency ( creatinine clearance 15 50 mL/min ) . Apixaban rivaroxaban appear best candidate since : - approve France VTE patient - mixed pathway elimination ( hepatic renal ) - several pharmacological similarity respective clinical trial show similar efficacy safety profile compare SOC VTE treatment . - need precede initial parenteral heparin contrary dabigatran edoxaban . This allow evaluate impact DOAs renally impair patient independently initial heparin effect - reduce dose regimen available approve AF - evaluation 2 DAOs allows evaluate concept new class renally impaired VTE patient independently pharmaceutical company . Finally plan evaluate reduced dos 2 DOAs ( apixaban , rivaroxaban ) compare SOC VTE patient moderate severe renal insufficiency term net clinical benefit ( recurrent VTE major bleed ) 3 month .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Patients moderate renal insufficiency define creatinine clearance 30 50 ml/min ( Cockcroft Gault formula ) severe renal insufficiency ( 15 29 ml/min ) Patients acute objectively confirm symptomatic proximal deepvein thrombosis ( DVT ) pulmonary embolism ( PE ) ( without deepvein thrombosis ) , plan treat least 3 month Patients &gt; 18 year Life expectancy 3 month Social security affiliation Signed informed consent Indication anticoagulant VTE Active bleeding high risk bleed contraindicate anticoagulant treatment ; systolic blood pressure 180 mm Hg diastolic blood pressure 110 mm Hg Anticoagulation 72 hour prior randomization Chronic liver disease chronic hepatitis Patient high risk bleed Creatinine clearance &lt; 15 ml/min end stage renal disease indication extrarenal dialysis Need concomitant antiplatelet therapy aspirin 75325 mg per day . However concomitant treatment aspirin discourage population bleeding risk . Concomitant use strong inhibitor cytochrome P450 3A4 ( CYP3A4 ) ( e.g. , protease inhibitor human immunodeficiency virus infection azoleantimycotics agent ketoconazole , itraconazole , voriconazole , posaconazole ) CYP3A4 inducer ( e.g. , rifampin , carbamazepine , phenytoin ) , Active pregnancy expect pregnancy effective contraception Any contraindication list local labeling UFH , LMWH VKA oral anticoagulant . Cancerassociated VTE require longterm treatment LMWH Life expectancy le 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Renal insufficiency</keyword>
	<keyword>Direct oral anticoagulant ( DOA )</keyword>
	<keyword>Deep Vein Thrombosis ( DVT )</keyword>
	<keyword>Pulmonary Embolism ( PE )</keyword>
	<keyword>Venous Thromboembolism ( VTE )</keyword>
	<keyword>Heparins</keyword>
</DOC>